CTOs on the Move

Immantics

www.immatics.com

 
Immatics Biotechnologies is a clinical-stage biopharmaceutical company leading the development of advanced immunotherapies that are active against cancer. Cancer immunotherapy is still severely constrained by the lack of novel targets. Immatics overcomes this by applying its target discovery engine XPRESIDENT® to identify and validate antigens specific to cancer cells. These antigens, also called Tumor-Associated Peptides (TUMAPs), are able to activate T cells which are responsible for identifying and destroying cancer cells. These well characterized TUMAPs can be used as targets for all of the most promising cancer immunotherapy approaches including Adoptive Cell Therapies (ACT), soluble T Cell Receptors (TCRs), Antibodies ...
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.immatics.com
  • 7000 Fannin Suite 2115, 2120
    Houston, TX USA 77030
  • Phone: 346.204.5400

Executives

Name Title Contact Details

Funding

Immantics raised $40.3M on 09/02/2015

Similar Companies

hhoaltd

hhoaltd is a Hinsdale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Statistical Center for HIV/AIDS Research and Prevention

Statistical Center for HIV/AIDS Research and Prevention is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Exonics Therapeutics

Exonics Therapeutics was launched in February 2017 to advance the research of our scientific founder, Dr. Eric Olson and his laboratory at the University of Texas Southwestern Medical Center (UTSW) to develop treatments for patients with neuromuscular diseases. Dr. Olson is one of the world’s leading experts in the study of muscle cells and the application of gene editing to treat these types of diseases. In particular, Dr. Olson’s laboratory has used adeno-associated virus (AAV) to deliver a CRISPR/Cas9 technology that can identify and repair exon mutations to restore the production of dystrophin, a protein that helps stabilize and protect muscle fibers. Dystrophin is the protein missing in boys with Duchenne. The loss of dystrophin causes Duchenne.

Ionpath

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath`s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis.

DuPont Pioneer

DuPont Pioneer headquartered in Des Moines, Iowa, is the world’s leading developer and supplier of advanced plant genetics, providing high-quality seeds to farmers in more than 90 countries. DuPont Pioneer provides agronomic support and services to help increase farmer productivity and profitability and strives to develop sustainable agricultural systems for people everywhere. Science with Service Delivering Success.